Abstract
Introduction: Acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for th......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
